Companies › Bionyra Pharma
1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BYN-001 humanized IgG1 monoclonal antibody targeting IL-25 | IL25 | Phase 1 | Atopic Dermatitis | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07746817 | BYN-001 | Phase 1 | Atopic Dermatitis | Immunology | Jun 2028 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.